https://www.selleckchem.com/pr....oducts/Fedratinib-SA
ter therapy]) occurring in 40.9%, class II (oligoprogressors [≤3 lesions at recurrence]) occurring in 36% (including 7.9% of patients with PSA recurrence but no metastatic disease), and class III (polyprogressors [3 lesions]) occurring in 23.1% of patients. After MDT, the majority of patients have long-term control or oligoprogression (class I or II). Recurrence tended to occur in osseous sites. These findings, if validated, have implications for future integration of MDT and clinical trial design. After MDT, t
Like
Comment
Share
